The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor

Nature Reviews Drug Discovery

Volumn 10, Issue 1, 2011, Pages 61-75

  Perzborn, Elisabeth ^a   Roehrig, Susanne ^b   Straub, Alexander ^b   Kubitza, Dagmar ^c   Misselwitz, Frank ^d  

^a Global Therapeutic Research   (United States)

^b Global Lead Generation and Optimization   (United States)

^c Global Clinical Pharmacology   (United States)

^d Global Clinical Development   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID; ACETYLSALICYLIC ACID; ANTISTASIN; ANTIVITAMIN K; APIXABAN; AZD 0837; BETRIXABAN; BLOOD CLOTTING FACTOR 10A; CL 1031; DABIGATRAN ETEXILATE; DIGOXIN; EDOXABAN; ENOXAPARIN; FIDEXABAN; FONDAPARINUX; FXV 673; HEPARIN; IDRABIOTAPARINUX; IDRAPARINUX; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; NAPROXEN; OTAMIXABAN; OXAZOLIDINONE DERIVATIVE; PLACEBO; PRADAX; RITONAVIR; RIVAROXABAN; RPR 130673; THROMBIN; UNCLASSIFIED DRUG; WARFARIN; YM 150;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; AREA UNDER THE CURVE; BINDING AFFINITY; BLEEDING; CRYSTAL STRUCTURE; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; HEART ATRIUM FIBRILLATION; HEMATOMA; HUMAN; IC 50; INTERNATIONAL NORMALIZED RATIO; LIVER FUNCTION; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; OPTIMAL DRUG DOSE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTHROMBIN TIME; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; STRUCTURE ACTIVITY RELATION; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; UNSTABLE ANGINA PECTORIS; VENOUS THROMBOEMBOLISM; WOUND CLOSURE;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FACTOR XA; HUMANS; MORPHOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 78650827771     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3185     Document Type: Review

References (157)

1. McLean, J. The thromboplastic action of cephalin. Am. J. Physiol. 41, 250-257 (1916).
2. Hirsh, J. et al. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133, 141S-159S (2008).
3. Warkentin, T. E., Greinacher, A., Koster, A., Lincoff, A. M. & American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133, 340S-380S (2008).
4. Warwick, D., Dahl, O. E. & Fisher, W. D. Orthopaedic thromboprophylaxis: limitations of current guidelines. J. Bone Joint Surg. Br. 90, 127-132 (2008).
5. Campbell, H. A. & Link, K. P. Studies on the hemorrhagic sweet clover disease. IV. The isolation and crystallization of the hemorrhagic agent. J. Biol. Chem. 138, 21-33 (1941).
6. Ansell, J. et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133, 160S-198S (2008).
7. Schwarz, U. I. et al. Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 358, 999-1008 (2008).
8. Klein, T. E. et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009).
9. Hirsh, J., O'Donnell, M. & Weitz, J. I. New anticoagulants. Blood 105, 453-463 (2005).
10. Weitz, J. I. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb. Haemost. 96, 274-284 (2006).
11. Dyke, C. K. et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 114, 2490-2497 (2006).
12. Eriksson, B. I. et al. Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J. Thromb. Haemost. 6, 457-463 (2008).
13. Goto, S. Factor XIa as a possible new target of antithrombotic therapy. J. Thromb. Haemost. 4, 1494-1495 (2006).
14. Schumacher, W. A. et al. Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats. Eur. J. Pharmacol. 570, 167-174 (2007).
15. Ho, S. J. & Brighton, T. A. Ximelagatran: direct thrombin inhibitor. Vasc. Health Risk Manag. 2, 49-58 (2006).
16. Nishio, H., Ieko, M. & Nakabayashi, T. New therapeutic option for thromboembolism - dabigatran etexilate. Expert Opin. Pharmacother. 9, 2509-2517 (2008).
17. Turpie, A. G. G., Eriksson, B. I., Lassen, M. R. & Bauer, K. A. Fondaparinux, the first selective factor Xa inhibitor. Curr. Opin. Hematol. 10, 327-332 (2003).
18. Carreiro, J. & Ansell, J. Apixaban, an oral direct factor Xa inhibitor: awaiting the verdict. Expert Opin. Investig. Drugs 17, 1937-1945 (2008).
19. Piccini, J. P., Patel, M. R., Mahaffey, K. W., Fox, K. A. & Califf, R. M. Rivaroxaban, an oral direct factor Xa inhibitor. Expert Opin. Investig. Drugs 17, 925-937 (2008).
20. Leadley, R. J. Coagulation factor Xa inhibition: biological background and rationale. Curr. Top. Med. Chem. 1, 151-159 (2001).
21. Kearon, C. et al. Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J. Thromb. Haemost. 3, 962-968 (2005).
22. Saito, H. et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J. Thromb. Haemost. 5, 31-41 (2007).
23. Bernard, G. R. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699-709 (2001).
24. Levi, M. & Van Der Poll, T. Recombinant human activated protein C: current insights into its mechanism of action. Crit. Care 1 1 (Suppl. 5), S3 (2007).
25. Ansell, J. Factor Xa or thrombin: is factor Xa a better target? J. Thromb. Haemost. 5 (Suppl. 1), 60-64 (2007).
26. Gerotziafas, G. T. & Samama, M. M. Heterogeneity of synthetic factor Xa inhibitors. Curr. Pharm. Des. 11, 3855-3876 (2005).
27. Turpie, A. G. G. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler. Thromb. Vasc. Biol. 27, 1238-1247 (2007).
28. Koller, F. History of factor X. Thromb. Diath. Haemorrh. 4, 58-65 (1960).
29. Brown, D. L. & Kouides, P. A. Diagnosis and treatment of inherited factor X deficiency. Haemophilia 14, 1176-1182 (2008).
30. Hougie, C., Barrow, H. M. & Graham, J. B. Stuart clotting defect. I. Segregation of a hereditary hemorrhagic state from the heterozygous heretofore called 'stable factor' (SPCA, proconvertin factor VII deficiency). J. Clin. Invest. 36, 485-493 (1957).
31. Telfer, T. P., Denson, K. W. & Wright, D. R. A 'new' coagulation defect. Br. J. Haematol. 2, 308-316 (1956).
32. Butenas, S., van't Veer, C. & Mann, K. G. "Normal" thrombin generation. Blood 94, 2169-2178 (1999).
33. Nutt, E. et al. The amino acid sequence of antistasin. A potent inhibitor of factor Xa reveals a repeated internal structure. J. Biol. Chem. 263, 10162-10167 (1988).
34. Tuszynski, G. P., Gasic, T. B. & Gasic, G. J. Isolation and characterization of antistasin. An inhibitor of metastasis and coagulation. J. Biol. Chem. 262, 9718-9723 (1987).
35. Dunwiddie, C. et al. Antistasin, a leech-derived inhibitor of factor Xa. Kinetic analysis of enzyme inhibition and identification of the reactive site. J. Biol. Chem. 264, 16694-16699 (1989).
36. Waxman, L., Smith, D. E., Arcuri, K. E. & Vlasuk, G. P. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 248, 593-596 (1990).
37. Nicolini, F. A. et al. Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis. Blood Coagul. Fibrinolysis 7, 39-48 (1996).
38. Vlasuk, G. P. et al. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb. Haemost. 65, 257-262 (1991).
39. Lynch, J. J. et al. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition. Cardiovasc. Res. 28, 78-85 (1994).
40. Sitko, G. R. et al. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation 85, 805-815 (1992).
41. Lefkovits, J. et al. Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model. J. Am. Coll. Cardiol. 28, 1858-1865 (1996).
42. Eisenberg, P. R., Siegel, J. E., Abendschein, D. R. & Miletich, J. P. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J. Clin. Invest. 91, 1877-1883 (1993).
43. Prager, N. A., Abendschein, D. R., McKenzie, C. R. & Eisenberg, P. R. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 92, 962-967 (1995).
44. McKenzie, C. R., Abendschein, D. R. & Eisenberg, P. R. Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa. Arterioscler. Thromb. Vasc. Biol. 16, 1285-1291 (1996).
45. Kotze, H. F., Lamprecht, S., Badenhorst, P. N., Roodt, J. P. & Van Wyk, V. Transient interruption of arterial thrombosis by inhibition of factor Xa results in long-term antithrombotic effects in baboons. Thromb. Haemost. 77, 1137-1142 (1997).
46. Gold, H. K. et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J. Am. Coll. Cardiol. 21, 1039-1047 (1993).
47. Theroux, P., Waters, D., Lam, J., Juneau, M. & McCans, J. Reactivation of unstable angina after the discontinuation of heparin. N. Engl. J. Med. 327, 141-145 (1992).
48. Hermans, C. & Claeys, D. Review of the rebound phenomenon in new anticoagulant treatments. Curr. Med. Res. Opin. 22, 471-481 (2006).
49. Furugohri, T. et al. Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models. Eur. J. Pharmacol. 514, 35-42 (2005).
50. Becker, R. C., Alexander, J., Dyke, C. K. & Harrington, R. A. Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. Thromb. Haemost. 92, 1182-1193 (2004).
51. Sato, K. et al. YM-60828, a novel factor Xa inhibitor: separation of its antithrombotic effects from its prolongation of bleeding time. Eur. J. Pharmacol. 339, 141-146 (1997).
52. Taniuchi, Y. et al. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa. Thromb. Haemost. 79, 543-548 (1998).
53. Hara, T. et al. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb. Haemost. 71, 314-319 (1994).
54. Fujii, Y. et al. Characteristics of gastrointestinal absorption of DX-9065a, a new synthetic anticoagulant. Drug Metab. Pharmacokinet. 22, 26-32 (2007).
55. Alexander, J. H. et al. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. J. Thromb. Haemost. 3, 439-447 (2005).
56. Bauer, K. A. et al. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. Cardiovasc. Drug Rev. 20, 37-52 (2002).
57. Bergqvist, D. Review of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgery. Vasc. Health Risk Manag. 2, 365-370 (2006).
58. Eriksson, B. I., Bauer, K. A., Lassen, M. R., Turpie, A. G. G. & Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N. Engl. J. Med. 345, 1298-1304 (2001).
59. Lassen, M. R., Bauer, K. A., Eriksson, B. I. & Turpie, A. G. G. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 359, 1715-1720 (2002).
60. Turpie, A. G. G., Bauer, K. A., Eriksson, B. I., Lassen, M. R. & PENTATHLON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 359, 1721-1726 (2002).
61. Bauer, K. A., Eriksson, B. I., Lassen, M. R. & Turpie, A. G. G. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N. Engl. J. Med. 345, 1305-1310 (2001).
62. Turpie, A. G. G., Bauer, K. A., Eriksson, B. I., Lassen, M. R. & Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch. Intern. Med. 162, 1833-1840 (2002).
63. Roehrig, S. et al. Discovery of the novel antithrombotic agent 5-chloro-N-([(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl] methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J. Med. Chem. 48, 5900-5908 (2005).
64. Lam, P. Y. et al. Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants. J. Med. Chem. 46, 4405-4418 (2003).
65. Pinto, D. J. et al. Discovery of 1-[3-(aminomethyl) phenyl]-N-3-fluoro-2- (methylsulfonyl)-[1,1-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5- carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J. Med. Chem. 44, 566-578 (2001).
66. Adler, M. et al. Crystal structures of two potent nonamidine inhibitors bound to factor Xa. Biochem. Mosc. 41, 15514-15523 (2002).
67. Choi-Sledeski, Y. M. et al. Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand. J. Med. Chem. 46, 681-684 (2003).
68. Maignan, S. et al. Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket. J. Med. Chem. 46, 685-690 (2003).
69. Mederski, W. W. et al. Chlorothiophenecarboxamides as P1 surrogates of inhibitors of blood coagulation factor Xa. Bioorg. Med. Chem. Lett. 14, 5817-5822 (2004).
70. Nazare, M. et al. Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure- activity relationship and X-ray crystallography. J. Med. Chem. 48, 4511-4525 (2005).
71. Perzborn, E. et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct factor Xa inhibitor. J. Thromb. Haemost. 3, 514-521 (2005).
72. Depasse, F. et al. Effect of BAY 59-7939 - a novel, oral, direct factor Xa inhibitor - on clot-bound factor Xa activity in vitro. J. Thromb. Haemost. Abstr. 3 (Suppl. 1), P1104 (2005).
73. Gerotziafas, G. T., Elalamy, I., Depasse, F., Perzborn, E. & Samama, M. M. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J. Thromb. Haemost. 5, 886-888 (2007).
74. Graff, J. et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J. Clin. Pharmacol. 47, 1398-1407 (2007).
75. Perzborn, E. & Harwardt, M. Direct thrombin inhibitors, but not factor Xa inhibitors, enhance thrombin formation in human plasma by interfering with the thrombin-thrombomodulin-protein C system. Blood (ASH Annual Meeting Abstracts) 11 2, 198-199 (2008).
76. Perzborn, E. et al. Biochemical and pharmacologic properties of BAY 59-7939, an oral, direct factor Xa inhibitor. Pathophysiol. Haemost. Thromb. 33 (Suppl. 2), PO079 (2004).
77. Perzborn, E. & Lange, U. Rivaroxaban - an oral, direct factor Xa inhibitor - inhibits tissue factor-mediated platelet aggregation. J. Thromb. Haemost. 5 (Suppl. 2), P-W-642 (2007).
78. Furugohri, T. et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J. Thromb. Haemost. 6, 1542-1549 (2008).
79. Shantsila, E. & Lip, G. Y. Apixaban, an oral, direct inhibitor of activated factor Xa. Curr. Opin. Investig. Drugs 9, 1020-1033 (2008).
80. Biemond, B. J. et al. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 59-7939) - an oral, direct factor Xa inhibitor. Thromb. Haemost. 97, 471-477 (2007).
81. Kubitza, D., Becka, M., Roth, A. & Mueck, W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr. Med. Res. Opin. 24, 2757-2765 (2008).
82. Kubitza, D., Becka, M., Wensing, G., Voith, B. & Zuehlsdorf, M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur. J. Clin. Pharmacol. 61, 873-880 (2005).
83. Gruber, A., Marzec, U. M., Buetehorn, U., Hanson, S.,Perzborn, E. Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates. Blood (ASH Annual Meeting Abstracts) 11 2,1307 (2008).
84. Perzborn, E., Trabandt, A., Selbach, K. & Tinel, H. Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats. J. Thromb. Haemost. 7 (Suppl. 2), 379 (2009).
85. Kubitza, D., Becka, M., Voith, B., Zuehlsdorf, M. & Wensing, G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin. Pharmacol. Ther. 78, 412-421 (2005).
86. Zhang, L., Reynolds, K. S., Zhao P. & Huang. S. M. Drug interactions evaluation: an integrated part of risk assessment of therapeutics. Toxicol. Appl. Pharmacol. 243, 134-145 (2010).
87. Zhang, L., Zhang, Y. D., Strong, J. M., Reynolds, K. S. & Huang, S. M. A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 38, 709-724 (2008).
88. Kubitza, D., Becka, M., Mueck, W. & Zuehlsdorf, M. Rivaroxaban (BAY 59-7939) - an oral, direct factor Xa inhibitor - has no clinically relevant interaction with naproxen. Br. J. Clin. Pharmacol. 63, 469-476 (2007).
89. Kubitza, D., Becka, M., Mueck, W. & Zuehlsdorf, M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct factor Xa inhibitor - are not affected by aspirin. J. Clin. Pharmacol. 46, 981-990 (2006).
90. Eriksson, B. I. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 358, 2765-2775 (2008).
91. Kakkar, A. K. et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372, 31-39 (2008). 92.
92. Lassen, M. R. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. 358, 2776-2786 (2008).
93. Turpie, A. G. G. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373, 1673-1680 (2009).
94. Weinz, C. et al. Pharmacokinetics of BAY 59-7939 - an oral, direct factor Xa inhibitor - in rats and dogs. Xenobiotica 35, 891-910 (2005).
95. Lang, D., Freudenberger, C. & Weinz, C. In vitro metabolism of rivaroxaban - an oral, direct factor Xa inhibitor - in liver microsomes and hepatocytes of rat, dog and man. Drug Metab. Dispos. 37, 1046-1055 (2009).
96. Weinz, C., Schwarz, T., Kubitza, D., Mueck, W. & Lang, D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs and humans. Drug Metab. Dispos. 37, 1056-1064 (2009).
97. Mueck, W. et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in patients undergoing major orthopaedic surgery. Clin. Pharmacokinet. 47, 203-216 (2008).
98. Mueck, W., Becka, M., Kubitza, D., Voith, B. & Zuehlsdorf, M. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in healthy subjects. Int. J. Clin. Pharmacol. Ther. 45, 335-344 (2007).
99. Kubitza, D., Becka, M., Zuehlsdorf, M. & Mueck, W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J. Clin. Pharmacol. 47, 218-226 (2007).
100. Kubitza, D. et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban - an oral, direct factor Xa inhibitor. Br. J. Clin. Pharmacol. 70, 703-712 (2010).
101. Halabi, A. et al. Effect of hepatic impairment on the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban - an oral, direct factor Xa inhibitor. J. Thromb. Haemost. 5 (Suppl. 2), P-M-635 (2007).
102. Eriksson, B. I. et al. Dose-escalation study of rivaroxaban (BAY 59-7939) - an oral, direct factor Xa inhibitor - for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb. Res. 120, 685-693 (2007).
103. Eriksson, B. I. et al. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 11 4, 2374-2381 (2006).
104. Eriksson, B. I. et al. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J. Thromb. Haemost. 4, 121-128 (2006).
105. Turpie, A. G. G. et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J. Thromb. Haemost. 3, 2479-2486 (2005).
106. Kubitza, D., Mueck, W. & Becka, M. Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation. Drug Saf. 31, 67-77 (2008).
107. Samama, M. M. et al. Suitability of chromogenic anti-FXa methods to measure rivaroxaban in human plasma. J. Thromb. Haemost. 7 (Suppl. 2), 693 (2009).
108. Karst, A., Bakowski-Enzian, B. & Perzborn, E. Monitoring of rivaroxaban: suitability of a well-established chromogenic anti-factor Xa assay. J. Thromb. Haemost. 7 (Suppl. 2), 372 (2009).
109. Fisher, W. D. et al. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb. Haemost. 97, 931-937 (2007).
110. Geerts, W. H. et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133, 381S-453S (2008).
111. Lassen, M. R. et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N. Engl. J. Med. 361, 594-604 (2009).
112. The RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J. Arthroplasty 24, 1-9 (2009).
113. Eriksson, B. I. et al. Oral rivaroxaban for the revention of symptomatic venous thromboembolism after elective hip and knee replacement. J. Bone Joint Surg. Br. 91, 636-644 (2009).
114. Mega, J. L. et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374, 29-38 (2009).
115. Bauer, K. A., Homering, M. & Berkowitz, S. D. Effects of age, weight, gender and renal function in a pooled analysis of four phase III studies of rivaroxaban for prevention of venous thromboembolism after major orthopedic surgery. Blood (ASH Annual Meeting Abstracts) 11 2, 166-167 (2008).
116. Agnelli, G. et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 11 6, 180-187 (2007).
117. Buller, H. R. et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study. Blood 11 2, 2242-2247 (2008).
118. Buller, H.R. Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension Study (Abstract 187). ASH Annual Meeting Abstracts [online], http://ash.confex.com/ash/2010/ webprogram/Paper32683.html (2010).
119. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New Engl. J. Med. 4 Dec 2010 (doi:10.1056/ NEJMoa1007903).
120. ROCKET AF Study Investigators. Rivaroxaban - once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am. Heart J. 159, 340-347 (2010).
121. Wong, P. C. et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J. Thromb. Haemost. 6, 820-829 (2008).
122. Luettgen, J. M. et al. Inhibition of measured thrombin generation in human plasma by apixaban: a predictive mathematical model based on experimentally determined rate constants. J. Thromb. Haemost. 5 (Suppl. 1), P-T-633 (2007).
123. Lassen, M. R. et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375, 807-815 (2010).
124. Lassen, M. R. et al. Randomized double-blind comparison of apixaban and enoxaparin for thromboprophylaxis after hip replacement: the ADVANCE-3 trial. Pathophysiol. Haemost. Thromb. 37, A20 (2010).
125. Alexander, J. H. et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 11 9, 2877-2885 (2009)
126. Eikelboom, J. W. et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am. Heart J. 159, 348-353 (2010).
127. Lopes, R. D. et al. Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: design and rationale. Am. Heart J. 159, 331-339 (2010).
128. Connolly, S. J. & Arnesen, H. AVERROES: apixaban versus acetylsalicylic acid to prevent strokes. European Society of Cardiology website [online] http://www.escardio.org/congresses/esc-2010/ congress-reports/ Documents/Tuesday/AVERROES-discussant-slides-Connolly.pdf (2010).
129. Zafar, M. U. et al. Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb. Haemost. 98, 883-888 (2007).
130. Fuji, T., Fujita, S., Tachibana, S. & Kawai, Y. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J. Thromb. Haemost. 8, 2458-2468 (2010).
131. Raskob, G. et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb. Haemost. 104, 642-649 (2010).
132. Weitz, J. I. et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb. Haemost. 104, 633-641 (2010).
133. Iwatsuki, Y. et al. Biochemical and pharmacological profiles of YM150, an oral direct factor Xa inhibitor. Blood (ASH Annual Meeting Abstracts) 108, 273a (2006).
134. Eriksson, B. I. et al. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J. Thromb. Haemost. 8, 714-721 (2010).
135. Sabatine, M. S. et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet 374, 787-795 (2009).
136. Cohen, M. et al. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation 11 5, 2642-2651 (2007).
137. Harenberg, J. Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Thromb. Haemost. 102, 811-815 (2009).
138. Veyrat-Follet, C., Vivier, N., Trellu, M., Dubruc, C. & Sanderink, G. J. The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials. J. Thromb. Haemost. 7, 559-565 (2009).
139. Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 371, 315-321 (2008).
140. Van Gogh Investigators et al. Idraparinux versus standard therapy for venous thromboembolic disease. N. Engl. J. Med. 357, 1094-1104 (2007).
141. Connolly, S. J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139-1151 (2009).
142. Eriksson, B. I. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370, 949-956 (2007).
143. Eriksson, B. I. et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J. Thromb. Haemost. 5, 2178-2185 (2007).
144. Schulman, S. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 361, 2342-2352 (2009).
145. Squizzato, A., Dentali, F., Steidl, L. & Ageno, W. New direct thrombin inhibitors. Intern. Emerg. Med. 4, 479-484 (2009).
146. Straub, A. et al. Substituted oxazolidinones and their use in the field of blood coagulation. WO0147919 (A1) (2001).
147. Mederski, W. W. et al. Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa. Bioorg. Med. Chem. Lett. 14, 3763-3769 (2004).
148. Pinto, D. J. et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2- oxopiperidin-1-yl) phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c] pyridine-3-carboxamide (Apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J. Med. Chem. 50, 5339-5356 (2007).
149. Kohrt, J. T. et al. The discovery of (2R,4R)-N-(4-chloro phenyl)-N-(2-fluoro-4-(2-oxopyridin-1(2H)-yl) phenyl)-4-methoxypyrrolidine-1,2- dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor. Chem. Biol. Drug Des. 70, 100-112 (2007).
150. Mann, K. G., Butenas, S. & Brummel, K. The dynamics of thrombin formation. Arterioscler. Thromb. Vasc. Biol. 23, 17-25 (2003).
151. Furie, B. & Furie, B. C. Mechanisms of thrombus formation. N. Engl. J. Med. 359, 938-949 (2008).
152. Mann, K. G., Jenny, R. J. & Krishnaswamy, S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Annu. Rev. Biochem. 57, 915-956 (1988).
153. Licari, L. G. & Kovacic, J. P. Thrombin physiology and pathophysiology. J. Vet. Emerg. Crit. Care (San Antonio) 19, 11-22 (2009).
154. Mann, K. G., Brummel, K. & Butenas, S. What is all that thrombin for? J. Thromb. Haemost. 1, 1504-1514 (2003).
155. Kaiser, B. Factor Xa-a promising target for drug development. Cell. Mol. Life Sci. 59, 189-192 (2002).
156. Wienen, W., Stassen, J. M., Priepke, H., Ries, U. J. & Hauel, N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb. Haemost. 98, 155-162 (2007).
157. Kakkar, A. K. et al. Extended thromboprophylaxis with rivaroxaban compared with short-term thromboprophylaxis with enoxaparin after total hip arthroplasty: the RECORD2 trial. Blood (ASH Annual Meeting Abstracts) 110, 307 (2007).